Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Portfolio Pulse from Benzinga Insights
Eli Lilly (NYSE:LLY) has received a range of analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased by 7.74% to $992.05. Analysts have maintained or raised their ratings, reflecting positive sentiment. Eli Lilly's financial performance is strong, with high revenue growth, net margin, and return on equity.
October 03, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly has received predominantly bullish analyst ratings, with a significant increase in the average 12-month price target. The company's strong financial performance, including high revenue growth and net margin, supports positive sentiment.
The article highlights a positive shift in analyst ratings for Eli Lilly, with a majority being bullish. The average price target has increased by 7.74%, indicating analysts' confidence in the company's future performance. Additionally, Eli Lilly's strong financial metrics, such as high revenue growth and net margin, further support the positive outlook. These factors are likely to have a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100